ALN-HBV: Phase I/II started

Alnylam began a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial of subcutaneous ALN-HBV. The trial will test single doses in up to 24 healthy volunteers and up to 28 patients ...